# Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor

> **NCT03977467** · PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 46 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer
- Solid Tumor

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Standard of Care Chemotherapy
- **DRUG:** Tiragolumab

## Key facts

- **NCT ID:** NCT03977467
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-30
- **Primary completion:** 2024-08-09
- **Final completion:** 2024-08-09
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2025-08-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03977467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03977467, "Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT03977467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*